Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The companys lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The companys product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
May 4, 2023
RegMed Investors’ (RMi) closing bell: sector barely wavers by earnings outcomes
May 1, 2023
RegMed Investors’ (RMi) closing bell: upside comes before it goes dark, or does it?
April 26, 2023
RegMed Investors’ (RMi) closing bell: Uncle algo showed briefly and left early
April 24, 2023
RegMed Investors’ (RMi) closing bell: calling the ball on underperforming share pricing, just too many factors to list
April 21, 2023
RegMed Investors’ (RMi) closing bell: the oversold cell and gene therapy sector was feeling the love
April 17, 2023
RegMed Investors’ (RMi) closing bell: sector share pricing rises after weeks of fear and dread
April 11, 2023
RegMed Investors’ (RMi) closing bell: a tug-of-war between sentiment and conviction as sector wavers and closes up
35 companies, 1 interpreter!
Insight, foresight and recommendation
Verastem (VSTM) -- Opened 2018 at $3.21, started February at $3.55 and March at $3.05 with a high of $3.24 on 3/6 - neeeds news which always stimulates volume and pricing offsetting complacency in share pricing ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors